also i'd add that the whole point of a phase I is to assess satefy and tolerability. I imagine that for immuno-oncology phase Is they select patients that have optimal prognosis....it's pretty hard to ascertain safety and tolerability for a given treatment that lasts years if the patients don't live that long.
Market Data 
Markets 
AI
